T-cell response to p53 tumor-associated antigen in patients with colorectal carcinoma

International Journal of Oncology

Volumn 28, Issue 2, 2006, Pages 431-438

  Bueter, Marco ^a   Gasser, Martin ^a   Schramm, Nicolai ^a   Lebedeva, Tatiana ^b   Tocco, Georges ^c   Gerstlauer, Christiane ^a   Grimm, Martin ^a   Nichiporuk, Ekaterina ^a   Thalheimer, Andreas ^a   Thiede, Arnulf ^a   Meyer, Detlef ^a   Benichou, Gilles ^c   Waaga Gasser, Ana Maria ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b AMERICAN RED CROSS   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer; Immune response; p53; T cells; Tumor antigens

Indexed keywords

CANCER ANTIBODY; CD4 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 2 RECEPTOR ALPHA; MESSENGER RNA; PROTEIN P53; TRANSCRIPTION FACTOR GATA 3;

ARTICLE; BIOSYNTHESIS; BLOOD; CANCER STAGING; CELL CULTURE; COLORECTAL TUMOR; EPITOPE MAPPING; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; PATHOLOGY; POINT MUTATION; T LYMPHOCYTE SUBPOPULATION; TH2 CELL; TUMOR ASSOCIATED LEUKOCYTE;

ANTIBODIES, NEOPLASM; ANTIGENS, CD4; CELLS, CULTURED; COLORECTAL NEOPLASMS; EPITOPE MAPPING; GATA3 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION; HUMANS; IMMUNOHISTOCHEMISTRY; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASM STAGING; POINT MUTATION; RNA, MESSENGER; T-LYMPHOCYTE SUBSETS; TH2 CELLS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 34548484680     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.28.2.431     Document Type: Article

References (41)

1. Hollstein M, Sidransky D, Vogelstein B and Harris CC: p53 mutations in human cancers. Science 253: 49-53, 1991.
2. Offringa R, Vierboom MP, van der Burg SH, Erdile L and Melief CJ: p53: a potential target antigen for immunotherapy of cancer. Ann NY Acad Sci 910: 223-233, 2000.
3. Mayordomo JI, Loftus DJ, Sakamoto H, et al: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J Exp Med 183: 1357-1365, 1996.
4. Vierboom MP, Bos GM, Ooms M, Offringa R and Melief CJ: Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int J Cancer 87: 253-260, 2000.
5. Van der Burg SH, De Cock K, Menon AG, et al: Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer. Eur J Immunol 31: 146-155, 2001.
6. Melief CJ, Toes RE, Medema JP, van der Burg SH, Ossendorp F and Offringa R: Strategies for immunotherapy of cancer. Adv Immunol 75: 235-282, 2000.
7. Hung K, Hayashi R, Lafond-Walker A, Lowenstein C, Pardoll D and Levitsky H: The central role of CD4(+) T cells in the antitumor immune response. J Exp Med 188: 2357-2368, 1998.
8. Fernandez NC, Lozier A, Flament C, et al: Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat Med 5: 405-411, 1999.
9. Romani N, Ratzinger G, Pfaller K, Salvenmoser W, Stossel H, Koch F and Stoitzner P: Migration of dendritic cells into lymphatics-the Langerhans cell example: routes, regulation, and relevance. Int Rev Cytol 207: 237-270, 2001.
10. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR and Fanger NA: Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL. J Exp Med 189: 1343-1354, 1999.
11. Zwaveling S, Vierboom MP, Ferreira Mota SC, et al: Antitumor efficacy of wild-type p53-specific CD4(+) T-helper cells. Cancer Res 62: 6187-6193, 2002.
12. Zwaveling S, van der Burg SH, Menon AG, Melief CJ and Offringa R: Immunotherapy of cancer through targeting of the p53 tumor antigen. Arch Immunol Ther Exp 50: 297-305, 2002.
13. Cabrera T, Angustias Fernandez M, Sierra A, et al: High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Hum Immunol 50: 127-134, 1996.
14. Garrido F, Ruiz-Cabello F, Cabrera T, Perez-Villar JJ, Lopez-Botet M, Duggan-Keen M and Stern PL: Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Immunol Today 18: 89-95, 1997.
15. Algarra I, Collado A and Garrido F: Altered MHC class I antigens in tumors. Int J Clin Lab Res 27: 95-102, 1997.
16. De Vries TJ, Fourkour A, Wobbes T, Verkroost G, Ruiter DJ and van Muijen GN: Heterogeneous expression of immunotherapy candidate proteins gp100, MART-1, and tyrosinase in human melanoma cell lines and in human melanocytic lesions. Cancer Res 57: 3223-3229, 1997.
17. + cytotoxic-T-cell responses: evidence for immunoselection of antigen-loss variants in vivo. Int J Cancer 66: 470-476, 1996.
18. Schwartz RH: A cell culture model for T lymphocyte clonal anergy. Science 248: 1349-1356, 1990.
19. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellstrom I and Hellstrom KE: Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 179: 523-532, 1994.
20. De Smedt T, van Mechelen M, De Becker G, Urbain J, Leo O and Moser M: Effect of interleukin-10 on dendritic cell maturation and function. Eur J Immunol 27: 1229-1235, 1997.
21. Almand B, Resser JR, Lindman B, et al: Clinical significance of defective dendritic cell differentiation in cancer. Clin Cancer Res 6: 1755-1766, 2000.
22. Menon AG, Janssen-van Rhijn CM, Morreau H, et al: Immune system and prognosis in colorectal cancer: a detailed immunohistochemical analysis. Lab Invest 84: 493-501, 2004.
23. Soussi T: p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60: 1777-1788, 2000.
24. Zalcman G, Tredaniel J, Schlichtholz B, et al: Prognostic significance of serum p53 antibodies in patients with limited-stage small cell lung cancer. Int J Cancer 89: 81-86, 2000.
25. Soussi T, Dehouche K and Beroud C: p53 website and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum Mutat 15: 105-113, 2000.
26. Winter SF, Minna JD, Johnson BE, Takahashi T, Gazdar AF and Carbone DP: Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation. Cancer Res 52: 4168-4174, 1992.
27. Vennegoor CJ, Nijman HW, Drijfhout JW, et al: Autoantibodies to p53 in ovarian cancer patients and healthy women: a comparison between whole p53 protein and 18-mer peptides for screening purposes. Cancer Lett 116: 93-101, 1997.
28. Tilkin AF, Lubin R, Soussi T, et al: Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 25: 1765-1769, 1995.
29. Carbone DP and Minna JD: In vivo gene therapy of human lung cancer using wild-type p53 delivered by retrovirus. J Natl Cancer Inst 86: 1437-1438, 1994.
30. Legros Y, Lafon C and Soussi T: Linear antigenic sites defined by the B-cell response to human p53 are localized predominantly in the amino and carboxy-termini of the protein. Oncogene 9: 2071-2076, 1994.
31. + T cell responses to self- and mutated p53 determinants during tumorigenesis in mice. J Immunol 164: 5641-5651, 2000.
32. Cabelguenne A, Blons H, De Waziers I, et al: p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma: a prospective series. J Clin Oncol 18: 1465-1473, 2000.
33. Chen HL and Carbone DP: p53 as a target for anti-cancer immunotherapy. Mol Med Today 3: 160-167, 1997.
34. Waaga AM, Gasser M, Kist-van Holthe JE, et al: Regulatory functions of self-restricted MHC class II allopeptide-specific Th2 clones in vivo. J Clin Invest 107: 909-916, 2001.
35. Yue FY, Dummer R, Geertsen R, Hofbauer G, Laine E, Manolio S and Burg G: Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules. Int J Cancer 71: 630-637, 1997.
36. Ludewig B, Graf D, Gelderblom HR, Becker Y, Kroczek RA and Pauli G: Spontaneous apoptosis of dendritic cells is efficiently inhibited by TRAP (CD40-ligand) and TNF-alpha, but strongly enhanced by interleukin-10. Eur J Immunol 25: 1943-1950, 1995.
37. Vogelstein B, Lane D and Levine AJ: Surfing the p53 network. Nature 408: 307-310, 2000.
38. Vousden KH and Lu X: Live or let die: the cel's response to p53. Nat Rev Cancer 2: 594-604, 2002.
39. Spiotto MT, Yu P, Rowley DA, et al: Increasing tumor antigen expression overcomes 'ignorance' to solid tumors via cross-presentation by bone marrow-derived stromal cells. Immunity 17: 737-747, 2002.
40. Messi M, Giacchetto I, Nagata K, Lanzavecchia A, Natoli G and Sallusto F: Memory and flexibility of cytokine gene expression as separable properties of human T(H)1 and T(H)2 lymphocytes. Nat Immunol 4: 78-86, 2003.
41. Moser B, Schaerli P and Loetscher P: CXCR5(+) T cells: follicular homing takes center stage in T-helper-cell responses. Trends Immunol 23: 250-254, 2002.